KNSA

Kiniksa Pharmaceuticals, Ltd.

Fundamental data last updated:October 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

BM

Next Earnings Date

Pending Announcement

Business Summary

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

 


Analyze KNSA on TradingView

VALUATION

P/E

53.25

Market Cap ($M USD)

$3.82B

Forward P/E

11.47

PEG

0.03

PRICE TO SALES

5.07

PRICE TO BOOK

6.42

EV / EBITDA

35.86

5-Year Average P/E

Free Cash Flow Yield

4.30%

DCF Value

$-728.20

Graham Number

$13.04

Price to FCF

23.27

EV to FCF

22.17

Earnings Yield

1.88%

FCF Yield

4.30%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.95

Next Year EPS Growth Estimate

$4.43

Next Year Revenue Growth Estimate

$1.58B

Return on Equity (ROE)

13.26%

FREE CASH FLOW

Operating Margin

12.36%

Debt-to-Equity

0.02

Piotroski F-Score

6

Altman Z-Score

12.06

Return on Invested Capital (ROIC)

13.94%

Current Ratio

3.79

Quick Ratio

3.33

Net Debt to EBITDA

-1.78

Interest Coverage

0.00

Gross Profit margin

54.63%

FCF PER SHARE

$2.15

REVENUE PER SHARE

$9.85

Analyze KNSA on TradingView

Gainseekers Quantitative Analysis

Summary

Kiniksa Pharmaceuticals, Ltd. is trading at a valuation that raises eyebrows. With a Price/Earnings ratio of 61.37, the market seems to be pricing in significant growth, yet the DCF value suggests a stark misalignment. The Forward P/E of 13.22 indicates optimism for future earnings, but the Earnings Yield of 1.63% is underwhelming. However, the Altman Z-score of 13.10 signals robust financial health, suggesting low bankruptcy risk. This juxtaposition of high valuation and financial stability paints a complex picture for potential investors.

AI Exposure / Tech Reliance

Operating in the Biotechnology sector, Kiniksa is well-positioned to leverage AI and tech advancements. The industry is ripe for innovation, and companies like Kiniksa can harness AI for drug discovery and personalized medicine. This adaptability is crucial for maintaining a competitive edge in a rapidly evolving landscape.

The Bull Case

For the discerning GARP investor, Kiniksa presents a compelling case. The ROIC of 13.94% reflects strong capital efficiency, while a Piotroski F-Score of 6 indicates solid financial health. With a Free Cash Flow Yield of 3.73%, the company demonstrates its ability to generate cash effectively. Its Operating Margin of 12.36% suggests pricing power, making it an attractive option for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, Kiniksa is not without risks. The Price/Book ratio of 7.40 and Price/Sales of 5.84 highlight a potentially overvalued stock. Trading near its 52-week high, the stock appears technically overextended. Furthermore, the EV to EBITDA ratio of 41.60 suggests the market may be overly optimistic about future earnings, posing a risk for value-conscious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$64.00

Institutional Ownership %

1-Year Beta

0.17

Insider Buying % (6 Mo)

Distance to 52-Week High

17.76%

Distance to 52-Week Low

48.33%

EARNINGS SURPRISE %

50.00%

50-DAY SMA

$50.09

200-DAY SMA

$42.72

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.